125 patents
Utility
Pharmaceutical Compositions Comprising 2,3,5-TRIMETHYL-6-NONYLCYCLOHEXA-2,5-DIENE-1,4-DIONE
4 Jan 24
Disclosed herein is pharmaceutical compositions of Compound 1, and/or the hydroquinone form thereof, and methods useful for treating or suppressing a disease or disorder such as an α-synucleinpathy, a tauopathy, an autistic spectrum disorder, a pervasive developmental disorder, a liver disease, and liver damage in a subject using such pharmaceutical compositions.
Swathi PINNAMANENI, Mandar V. DALI, Dhaval PATEL, Akm Nasir UDDIN
Filed: 6 Sep 23
Utility
Heterocyclic and heteroaryl compounds for treating Huntington's disease
2 Jan 24
Nadiya Sydorenko, Md Rauful Alam, Michael A. Arnold, Suresh Babu, Anuradha Bhattacharyya, Guangming Chen, Aleksey I. Gerasyuto, Gary Mitchell Karp, Andrew J. Kassick, Anthony R. Mazzotti, Young-Choon Moon, Jana Narasimhan, Jigar Patel, Anthony Turpoff, Matthew G. Woll, Wuming Yan, Nanjing Zhang
Filed: 25 Jun 19
Utility
Tablet for Use In Treating Huntington's Disease and Method of Making the Same
21 Dec 23
The present description relates to a tablet formulation of 2-[3-(2,2,6,6-tetramethylpiperidin-4-yl)-3H-[1,2,3]triazolo[4,5-c]pyridazin-6-yl]-5-(2H-1,2,3-triazol-2-yl)phenol, a compound for use in treating Huntington's disease, and a method of making the same.
Swathi Pinnamaneni, Akm Nasir Uddin, Mandar Vasant Dali
Filed: 12 Nov 21
Utility
4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases
12 Dec 23
Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, and stroke (MELAS), Kearns-Sayre Syndrome (KSS), are disclosed, as well as compounds useful in the methods of the invention, such as 4-(p-quinolyl)-2-hydroxybutanamide derivatives.
Orion D. Jankowski, Kieron E. Wesson, Paul Mollard, William D. Shrader
Filed: 22 Feb 21
Utility
Compounds for treating spinal muscular atrophy
28 Nov 23
Hasane Ratni, Luke Green, Marla L. Weetall, Nikolai A. Naryshkin
Filed: 16 Nov 20
Utility
Polymorphic Forms of (R)-2-HYDROXY-2-METHYL-4-(2,4,5-TRIMETHYL-3,6-DIOXOCYCLOHEXA-1,4-DIENYL)BUTANAMIDE
16 Nov 23
Disclosed herein are polymorphic and amorphous forms of anhydrate, hydrate, and solvates of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide and methods of using such compositions for treating or suppressing oxidative stress disorders, including mitochondrial disorders, impaired energy processing disorders, neurodegenerative diseases and diseases of aging.
Paul MOLLARD, Peter GIANNOUSIS, Shazad SUCHIT, Mahmoud MIRMEHRABI, Christopher R. CORNELL, Kieron E. WESSON
Filed: 5 Jul 23
Utility
2,3,5-TRIMETHYL-6-NONYLCYCLOHEXA-2,5-DIENE-1,4-DIONE for Suppressing and Treating Alpha-synucleinopathies, Tauopathies, and Other Disorders
26 Oct 23
Disclosed herein are methods of treating or suppressing a disorder selected from the group consisting of α-synucleinopathies, tauopathies, ALS, traumatic brain injury, and ischemic-reperfusion related injuries.ury, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of the formula: or the hydroquinone form thereof; or a solvate or hydrate thereof.
Andrew W. Hinman, Charles R. Holst, Angela Minnella, Paul Mollard, Sean Pintchovski, Jeffrey K. Trimmer, Eric Torrey
Filed: 5 Jul 23
Utility
Compounds for Treating Huntington's Disease
19 Oct 23
Nadiya Sydorenko, Md Rauful Alam, Lukiana Amedzo, Suresh Babu, Ramil Y. Baiazitov, Scott J. Barraza, Anuradha Bhattacharyya, Gary Mitchell Karp, Nathaniel T. Kenton, Anthony R. Mazzotti, Young-Choon Moon, Nicholas W. Mszar, Jana Narasimhan, Sudipta Pal, Jigar S. Patel, Anthony Turpoff, Matthew G. Woll, Zhenrong Xu, Nanjing Zhang
Filed: 16 Jun 23
Utility
Pharmaceutical compositions comprising 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione
17 Oct 23
Disclosed herein is pharmaceutical compositions of Compound 1, and/or the hydroquinone form thereof, and methods useful for treating or suppressing a disease or disorder such as an α-synucleinpathy, a tauopathy, an autistic spectrum disorder, a pervasive developmental disorder, a liver disease, and liver damage in a subject using such pharmaceutical compositions.
Swathi Pinnamaneni, Mandar V. Dali, Dhaval Patel, Akm Nasir Uddin
Filed: 8 Jul 22
Utility
Compounds for treating Huntington's disease
10 Oct 23
Nadiya Sydorenko, Md Rauful Alam, Lukiana Amedzo, Suresh Babu, Ramil Y. Baiazitov, Scott J. Barraza, Anuradha Bhattacharyya, Gary Mitchell Karp, Nathaniel T. Kenton, Anthony R. Mazzotti, Young-Choon Moon, Nicholas W. Mszar, Jana Narasimhan, Sudipta Pal, Jigar S. Patel, Anthony Turpoff, Matthew G. Woll, Zhenrong Xu, Nanjing Zhang
Filed: 27 Mar 19
Utility
Methods for Modulating Rna Splicing
5 Oct 23
In one aspect, described herein is a recognition element for splicing modifier (REMS) that can be recognized by a compound provided herein.
Nikolai Naryshkin, Amal Dakka
Filed: 3 Feb 23
Utility
Compounds for treating spinal muscular atrophy
12 Sep 23
Hongyan Qi, Soongyu Choi, Amal Dakka, Gary Mitchell Karp, Jana Narasimhan, Nikolai Naryshkin, Anthony A. Yurpoff, Marla L. Weetall, Ellen Welch, Matthew G. Woll, Tianle Yang, Nanjing Zhang, Xiaoyan Zhang, Xin Zhao, Luke Green, Emmanuel Pinard, Hasane Ratni
Filed: 5 Oct 20
Utility
2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and treating alpha-synucleinopathies, tauopathies, and other disorders
5 Sep 23
Andrew W. Hinman, Charles R. Holst, Angela Minnella, Paul Mollard, Sean Pintchovski, Jeffrey K. Trimmer, Eric Torrey
Filed: 25 Jan 22
Utility
Methods for Modulating Rna Splicing
31 Aug 23
In one aspect, described herein is an intronic recognition element for splicing modifier (iREMS) that can be recognized by a compound provided herein.
Anuradha Bhattacharyya, Amal Dakka, Kerstin Effenberger, Vijayalakshmi Gabbeta, Wencheng Li, Nikolai Naryshkin, Christopher Trotta, Kari Wiedinger
Filed: 12 May 23
Utility
Compounds for Treating Huntington's Disease
27 Jul 23
Nadiya Sydorenko, Rauful Alam, Suresh Babu, Anuradha Bhattacharyya, Guangming Chen, Matteo Chierchia, Gary Mitchell Karp, Tom Tuan Luong, Anthony R. Mazzotti, Young-Choon Moon, Nicholas Walter Mszar, Jana Narasimhan, Jigar S. Patel, Hongyu Ren, Gang Wang, Matthew G. Woll, Nanjing Zhang, Xiaoyan Zhang
Filed: 8 Apr 21
Utility
Methods for modulating RNA splicing
18 Jul 23
In one aspect, described herein is an intronic recognition element for splicing modifier (iREMS) that can be recognized by a compound provided herein.
Anuradha Bhattacharyya, Amal Dakka, Kerstin Effenberger, Vijayalakshmi Gabbeta, Wencheng Li, Nikolai Naryshkin, Christopher Trotta, Kari Wiedinger
Filed: 27 Nov 17
Utility
Compositions for an Orally Active 1,2,4-OXADIAZOLE for the Treatment of Disease
13 Jul 23
The present invention relates to specific doses of and dosing regimens for using a 1,2,4-oxadiazole benzoic acid compound in treating or preventing diseases associated with nonsense mutations.
Samit Hirwat, Langdon Miller
Filed: 11 Oct 22
Utility
Methods for Treating Huntington’s Disease
29 Jun 23
Suresh Babu, Anuradha Bhattacharyya, Seongwoo Hwang, Minakshi Jani, Young-choon Moon, Nadiya Sydorenko
Filed: 17 Feb 23
Utility
Heteroaryl compounds for treating Huntington's disease
27 Jun 23
Guangming Chen, Anuradha Bhattacharyya, Yao Jiang, Gary Mitchell Karp, Jana Narasimhan, Anthony Turpoff, Nanjing Zhang
Filed: 25 Jun 19
Utility
Methods for treating Huntington's disease
2 May 23
Suresh Babu, Anuradha Bhattacharyya, Seongwoo Hwang, Minakshi Jani, Young-choon Moon, Nadiya Sydorenko
Filed: 9 Nov 20